Jong Jin Oh | Urology | Research Excellence Award

Prof. Dr. Jong Jin Oh | Urology | Research Excellence Award

Seoul National University Bundang Hospital, South Korea

Prof. Dr. Jong Jin Oh is a distinguished South Korean urologic oncologist and academic researcher specializing in prostate cancer, bladder cancer, renal cell carcinoma, and precision urology. He earned his M.D., M.P.H., and Ph.D. from CHA University and has built an internationally recognized career combining clinical excellence with translational cancer research. His scholarly contributions include extensive work in polygenic risk scoring, genome-wide association studies, robotic urologic surgery, and oncological outcomes. Through numerous high-impact publications, he has significantly advanced precision medicine and minimally invasive urologic oncology.

Education

Prof. Dr. Jong Jin Oh completed his Doctor of Medicine (M.D.) degree in 2005 from the College of Medicine at CHA University, followed by a Master of Public Health (M.P.H.) in 2009 and a Ph.D. in 2015 from the same institution. His postgraduate clinical training included an internship and residency in urology at CHA Bundang Medical Center, where he developed expertise in urologic surgery and cancer management. He later completed a prestigious fellowship in the Department of Urology at Seoul National University Bundang Hospital, focusing on advanced urologic oncology and minimally invasive surgical techniques. His educational background reflects a strong integration of medicine, public health, and translational cancer research.

Professional Experience

Prof. Dr. Jong Jin Oh has held several distinguished academic and clinical appointments throughout his career. He began as an Assistant Professor at CHA University and simultaneously served as a Research Professor at the CHA Cancer Research Institute. He later joined Seoul National University Bundang Hospital, where he progressed from Assistant Professor to Associate Professor and currently serves as Professor in the Department of Urology at Seoul National University College of Medicine. His professional career has been marked by leadership in robotic surgery, urologic oncology, and precision medicine research, contributing substantially to both patient care and academic advancement.

Research Interest

The research interests of Prof. Dr. Jong Jin Oh primarily focus on prostate cancer genomics, bladder cancer prognosis, renal cell carcinoma, robotic-assisted urologic surgery, and personalized cancer therapy. He has conducted pioneering studies on polygenic risk scores, exome-wide association studies, and genetic biomarkers for predicting prostate cancer progression and recurrence. His work also explores oncological outcomes after radical prostatectomy and cystectomy, as well as innovative rehabilitation approaches for urinary incontinence. Additionally, he has contributed to investigations on electromagnetic radiation effects on male fertility and advanced predictive models for urologic malignancies. His multidisciplinary approach integrates genomics, clinical oncology, and minimally invasive surgical innovation.

Award and Honor

Throughout his academic and clinical career, Prof. Dr. Jong Jin Oh has earned widespread recognition for his outstanding contributions to urologic oncology and cancer genomics research. His appointment as Professor at Seoul National University College of Medicine reflects his distinguished reputation in the medical community. He has authored numerous influential publications in internationally respected journals such as BJU International, Scientific Reports, and Frontiers in Oncology. His innovative studies in prostate cancer genetics and robotic urologic surgery have strengthened his international standing as a leading researcher and clinician in urology.

Conclusion

Prof. Dr. Jong Jin Oh has established himself as a globally respected expert in urologic oncology through his exceptional achievements in clinical medicine, academic leadership, and translational cancer research. His work in genomic risk prediction, robotic surgery, and precision oncology has contributed significantly to improving diagnostic accuracy and treatment outcomes for prostate and bladder cancer patients. With a strong foundation in education, extensive professional experience, and a prolific research portfolio, he continues to influence the future of modern urology. His dedication to innovation and patient-centered care positions him among the leading scholars in contemporary urologic medicine.

Publications Top Noted

 

Dr. Panupong Hansrivijit | Nephrology | Best Researcher Award

Dr. Panupong Hansrivijit | Nephrology | Best Researcher Award

Brigham and Women's Hospital, United States.

Dr. Panupong (Ben) Hansrivijit, MD, is a dedicated nephrology fellow at Brigham and Women’s Hospital/Massachusetts General Hospital, Boston, MA. With a stellar academic background, including an MD with first-class honors from Chulalongkorn University, Dr. Hansrivijit focuses on advancing care for kidney-related conditions. His clinical expertise spans chronic kidney disease, dialysis, and kidney transplantation, alongside a robust research portfolio in nephrology and public health.

Profile

Google Scholar

🎓 Education

Dr. Panupong Hansrivijit is a nephrology fellow at Brigham and Women’s Hospital/Massachusetts General Hospital (2022–2026) and a Master of Public Health candidate at Harvard T.H. Chan School of Public Health (2023–2025). He completed his Internal Medicine Residency at UPMC Harrisburg (2019–2022) and earned his MD with First Class Honors from Chulalongkorn University, Thailand (2016). Dr. Hansrivijit is committed to advancing nephrology and public health through patient care and research.

🏥 Experience

Dr. Panupong Hansrivijit is a dedicated nephrology fellow at Brigham and Women’s Hospital/Massachusetts General Hospital (2022–2026), specializing in kidney care, dialysis, and transplant evaluations. He previously honed his clinical and research expertise during his Internal Medicine Residency at UPMC Harrisburg (2019–2022) and built a strong foundation in patient care as an Internal Medicine Intern at Thammasat University Hospital (2016–2019). Dr. Hansrivijit is passionate about advancing nephrology through clinical excellence and research innovation.

🔬 Research Interests

Chronic kidney disease

Dialysis and dialysis access

Kidney transplantation

Acute kidney injury

Nephrotic syndrome

Hypertension

Pharmaco-epidemiology

🏆 Awards

American Board of Internal Medicine Certification (2022–2032)

Medical License (Massachusetts, 2022–2025)

📚 Selected Publications

Utilization Trends of Tirzepatide, Glucose-Lowering Medications, and Anti-Obesity Medications in Patients with CKD with and without Type 2 Diabetes: SA-PO327
Journal of the American Society of Nephrology, 35 (10S), 10.1681, 2024
Co-authored with J. Ortega-Montiel, D.J. Wexler, E. Patorno, and J.M. Paik, this study explores medication trends in patients with chronic kidney disease (CKD) and type 2 diabetes.

1403-P: Prescribing Trends of Glucose-Lowering Medications among Adult Kidney Transplant Recipients with Type 2 Diabetes—A US Population-Based Cohort Study
Diabetes, 73 (Supplement_1), 2024
In this population-based study, Dr. Hansrivijit, along with collaborators E. Patorno, D.J. Wexler, R. Abdi, and J.M. Paik, examines trends in glucose-lowering medication prescriptions among kidney transplant recipients.

Improvement of Calcinosis Cutis With Sodium Thiosulfate Infusion in a Peritoneal Dialysis Patient: SA-PO338
Journal of the American Society of Nephrology, 33 (11S), 697-698, 2022
A study co-authored with V.S. Iyer, highlighting the therapeutic effect of sodium thiosulfate in treating calcinosis cutis in a peritoneal dialysis patient.

Re: Incidence and Characteristics of Kidney Stones in Patients on Ketogenic Diet: A Systematic Review and Meta-Analysis
Journal of Urology, 207 (2), 462-463, 2022
Dr. Hansrivijit contributed to a meta-analysis investigating kidney stone incidences in patients following a ketogenic diet.

Hyperuricemia is Associated With Increased Mortality in Heart Failure Patients With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis
This study investigates the link between hyperuricemia and mortality risk in heart failure patients with preserved ejection fraction.